Voyager Therapeutics COO Robin Swartz sells $16,549 in stock

Robin Swartz, Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On February 20, Swartz sold 3,894 shares of common stock, generating proceeds of approximately $16,549. The sale was conducted at a weighted average price of $4.25 per share, with individual transaction prices ranging from $4.22 to $4.33. The transaction comes as the stock trades near its 52-week low, with InvestingPro data showing the company is currently undervalued despite maintaining a strong financial health score.

In addition to the sale, Swartz acquired 71,250 shares through restricted stock units (RSUs) on February 21, as part of Voyager’s 2015 Stock Option and Incentive Plan. These RSUs were granted at no cost and will vest over a three-year period. Furthermore, Swartz was awarded stock options for 142,500 shares, also under the same plan, which will vest over four years. The company, currently valued at $225 million, maintains robust liquidity with a current ratio of 8.45.

These transactions reflect Swartz’s ongoing participation in Voyager’s equity compensation program, which aligns the interests of executives with those of shareholders. InvestingPro subscribers can access detailed insider trading patterns and 10+ additional ProTips about VYGR’s financial health and market position through comprehensive Pro Research Reports.

In other recent news, Voyager Therapeutics announced a delay in its investigational new drug (IND) application for its ALS gene therapy candidate, VY9323, due to the need for alternative payloads. The company plans to reassess the payload component while maintaining the novel capsid component, which has shown consistent performance. Despite this setback, Voyager anticipates IND filings in 2025 for other gene therapy candidates targeting GBA1 Parkinson’s disease and Friedreich’s ataxia in collaboration with Neurocrine (NASDAQ:NBIX) Biosciences. Voyager’s financial outlook remains stable, with cash reserves projected to support operations into mid-2027.

Analysts at H.C. Wainwright and Citi have both expressed confidence in Voyager’s potential. H.C. Wainwright maintains a Buy rating with a $30 price target, citing optimism about the company’s CNS-focused pipeline. Meanwhile, Citi also initiated coverage with a Buy rating and a $12 price target, highlighting the company’s innovative TRACER platform. Voyager’s programs, including those for Alzheimer’s and SOD1-associated ALS, continue to progress, with significant developments expected in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.